6-hydroxy-hex-4-yn-3-one | 52804-63-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 6-hydroxy-hex-4-yn-3-one
• 英文别名: 6-Hydroxyhex-4-yn-3-one；6-hydroxyhex-4-yn-3-one
• CAS: 52804-63-4
• 化学式: C₆H₈O₂
• 分子量: 112.128
• InChiKey: DKLLSKRLKZVHBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  6-(tetrahydropyran-2-yloxy)hex-4-yn-3-one 在 硫酸 作用下， 以 甲醇 为溶剂， 生成 6-hydroxy-hex-4-yn-3-one
  参考文献：
  名称：

  Synthesis of 4-Oxo-2-alkyn-1-ols

  摘要：

  DOI：

  10.1055/s-1974-23320

文献信息

• [EN] BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE<br/>[FR] INHIBITEURS BICYCLIQUES PONTÉS DE MÉNINE-MLL ET MÉTHODES D'UTILISATION
  申请人：KURA ONCOLOGY INC

  公开号：WO2017161002A1

  公开（公告）日：2017-09-21

  The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.

  本公开提供了抑制menin与MLL1、MLL2和MLL融合致癌蛋白相互作用的方法。这些方法对于治疗白血病、实体肿瘤、糖尿病和其他依赖于MLL1、MLL2、MLL融合蛋白和/或menin活性的疾病是有用的。同时还提供了用于这些方法的组合物。
• INHIBITORS OF KRAS G12C MUTANT PROTEINS
  申请人：Araxes Pharma LLC

  公开号：US20160108019A1

  公开（公告）日：2016-04-21

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein R 1 , R 2 , R 3a , R 3b , R 4a , R 4b , G 1 , G 2 , L, m 1 , m 2 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  提供了作为G12C突变KRAS蛋白抑制剂活性的化合物。该化合物具有以下结构（I）：或其药学上可接受的盐、互变异构体、立体异构体或前药，其中R1、R2、R3a、R3b、R4a、R4b、G1、G2、L、m1、m2和E的定义如本文所述。还提供了与制备和使用这种化合物相关的方法，包括包含这种化合物的制药组合物以及用于治疗癌症等疾病的调节G12C突变KRAS蛋白活性的方法。
• SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Araxes Pharma LLC

  公开号：US20170022184A1

  公开（公告）日：2017-01-26

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R, R 1 , R 2a , R 2b , R 2c , A, B, L 1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.